Becerra, C., Spira, A. I., Conkling, P. R., Richey, S. L., Hanna, W. T., Cote, G. M., … Li, C. (2016). A phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in advanced non-small cell lung cancer. In Journal of Clinical Oncology (Vol. 34, pp. 9093–9093). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.9093

Becerra, Carlos, Alexander I. Spira, Paul R. Conkling, Stephen Lane Richey, Wahid Tewfik Hanna, Gregory Michael Cote, Rebecca Suk Heist, et al. “A phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in advanced non-small cell lung cancer.” In Journal of Clinical Oncology, 34:9093–9093. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.9093.

Becerra C, Spira AI, Conkling PR, Richey SL, Hanna WT, Cote GM, et al. A phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in advanced non-small cell lung cancer. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 9093–9093.

Becerra, Carlos, et al. “A phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in advanced non-small cell lung cancer.” Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. 9093–9093. Crossref, doi:10.1200/jco.2016.34.15_suppl.9093.

Becerra C, Spira AI, Conkling PR, Richey SL, Hanna WT, Cote GM, Heist RS, Langleben A, Laurie SA, Edenfield WJ, Kossler K, Hume S, Li Y, Hitron M, Li C. A phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in advanced non-small cell lung cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 9093–9093.